Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

1 results
12:00 AM, Oct 06, 2016  |  BC Innovations | Distillery Therapeutics

Therapeutics: Glycogen dependent kinase 3 (GSK3); dyskerin pseudouridine synthase 1 (DKC1)

studies suggest GSK3 inhibitors could help treat dyskeratosis congenita, which is caused by mutations in DKC1
symptoms. In intestinal cells generated from induced pluripotent stem (iPS) cells derived from patients harboring DKC1
mutations or from healthy volunteers that were engineered to express disease-related DKC1 mutations, a GSK3 inhibitor …